IMM-101 is a heat-killed innate and adaptive immune-activating mycobacterial product; a phase I study aimed to determine its safety and tolerability in individuals with melanoma

Journal: Annals of Oncology
Author[s]: J. Stebbing, A. Dalgleish, A. Gifford-Moore, A. Martin, C. Gleeson, G. Wilson, L. R. Brunet, J. Grange & S. Mudan Date: 19 September 2011
DOI: 10.1093/annonc/mdr363